{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:15:30Z","timestamp":1780503330765,"version":"3.54.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-022-10275-1","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T02:02:34Z","timestamp":1665021754000},"page":"949-959","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Sex-specific differences in the efficacy of heart failure therapies: a meta-analysis of 84,818 patients"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8197-5090","authenticated-orcid":false,"given":"Nelson","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Sawant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Sindone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"issue":"15","key":"10275_CR1","first-page":"1","volume":"5","author":"G Lippi","year":"2020","unstructured":"Lippi G, Sanchis-Gomar F (2020) Global epidemiology and future trends of heart failure. AME Med J 5(15):1\u20136","journal-title":"AME Med J"},{"key":"10275_CR2","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez\u2010Sell\u00e9s M, Doughty RN, Poppe K et al (2012) Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta\u2010analysis. Euro J Heart Fail 14(5):473\u2013479","DOI":"10.1093\/eurjhf\/hfs026"},{"issue":"24","key":"10275_CR3","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1161\/CIRCULATIONAHA.106.673442","volume":"115","author":"E O\u2019Meara","year":"2007","unstructured":"O\u2019Meara E, Clayton T, McEntegart MB et al (2007) Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation 115(24):3111\u20133120","journal-title":"Circulation"},{"issue":"18","key":"10275_CR4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa020265","volume":"347","author":"D Levy","year":"2002","unstructured":"Levy D, Kenchaiah S, Larson MG et al (2002) Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347(18):1397\u20131402","journal-title":"N Engl J Med"},{"key":"10275_CR5","doi-asserted-by":"crossref","unstructured":"Yancy CW, Fonarow GC, Albert NM et al (2009) Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Am Heart J 157(4):754\u2013762. e2","DOI":"10.1016\/j.ahj.2008.12.016"},{"key":"10275_CR6","doi-asserted-by":"publisher","unstructured":"ESOLVD Investigators (1991)\u00a0ffect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England J Med 325(5):293\u2013302. https:\/\/doi.org\/10.1056\/nejm199108013250501","DOI":"10.1056\/nejm199108013250501"},{"issue":"10","key":"10275_CR7","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1056\/nejm199209033271001","volume":"327","author":"MA Pfeffer","year":"1992","unstructured":"Pfeffer MA, Braunwald E, Moy\u00e9 LA et al (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 327(10):669\u2013677. https:\/\/doi.org\/10.1056\/nejm199209033271001","journal-title":"N Engl J Med"},{"key":"10275_CR8","doi-asserted-by":"publisher","unstructured":"CIBIs Investigators (1994)\u00a0A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 90(4):1765\u201373. (In eng). https:\/\/doi.org\/10.1161\/01.cir.90.4.1765","DOI":"10.1161\/01.cir.90.4.1765"},{"issue":"25","key":"10275_CR9","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1056\/nejm199512213332503","volume":"333","author":"L K\u00f8ber","year":"1995","unstructured":"K\u00f8ber L, Torp-Pedersen C, Carlsen JE et al (1995) A clinical trial of the angiotensin-converting\u2013enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333(25):1670\u20131676. https:\/\/doi.org\/10.1056\/nejm199512213332503","journal-title":"N Engl J Med"},{"issue":"21","key":"10275_CR10","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/nejm199605233342101","volume":"334","author":"M Packer","year":"1996","unstructured":"Packer M, Bristow MR, Cohn JN et al (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334(21):1349\u20131355. https:\/\/doi.org\/10.1056\/nejm199605233342101","journal-title":"N Engl J Med"},{"issue":"9169","key":"10275_CR11","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"Effect of metoprolol CR\/XL in chronic heart failure","year":"1999","unstructured":"Effect of metoprolol CR\/XL in chronic heart failure (1999) Metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353(9169):2001\u20132007 ((In eng))","journal-title":"Lancet"},{"key":"10275_CR12","doi-asserted-by":"publisher","unstructured":"Shekelle PG, Rich MW, Morton SC et al (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41(9):1529\u201338. (In eng). https:\/\/doi.org\/10.1016\/s0735-1097(03)00262-6","DOI":"10.1016\/s0735-1097(03)00262-6"},{"issue":"5","key":"10275_CR13","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/ejhf.1740","volume":"22","author":"X Rossello","year":"2020","unstructured":"Rossello X, Ferreira JP, Pocock SJ et al (2020) Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. Eur J Heart Fail 22(5):834\u2013844","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10275_CR14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.jacc.2010.06.061","volume":"57","author":"A Arshad","year":"2011","unstructured":"Arshad A, Moss AJ, Foster E et al (2011) Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol 57(7):813\u2013820","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10275_CR15","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1001\/archinternmed.2009.255","volume":"169","author":"H Ghanbari","year":"2009","unstructured":"Ghanbari H, Dalloul G, Hasan R et al (2009) Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. Arch Intern Med 169(16):1500\u20131506","journal-title":"Arch Intern Med"},{"issue":"7","key":"10275_CR16","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.hrthm.2010.03.042","volume":"7","author":"P Santangeli","year":"2010","unstructured":"Santangeli P, Pelargonio G, Russo AD et al (2010) Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. Heart Rhythm 7(7):876\u2013882","journal-title":"Heart Rhythm"},{"key":"10275_CR17","doi-asserted-by":"crossref","unstructured":"EUGenMed, Group CCS, Regitz-Zagrosek V et al (2016) Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Euro Heart J 37(1):24\u201334","DOI":"10.1093\/eurheartj\/ehv598"},{"issue":"10","key":"10275_CR18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):e1\u2013e34","journal-title":"J Clin Epidemiol"},{"issue":"22","key":"10275_CR19","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1136\/heartjnl-2019-315299","volume":"105","author":"M Woodward","year":"2019","unstructured":"Woodward M (2019) Rationale and tutorial for analysing and reporting sex differences in cardiovascular associations. Heart 105(22):1701\u20131708","journal-title":"Heart"},{"key":"10275_CR20","doi-asserted-by":"crossref","unstructured":"Woodward M (2013) Epidemiology: study design and data analysis: CRC press","DOI":"10.1201\/b16343"},{"key":"10275_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"issue":"17","key":"10275_CR22","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS et al (2019) Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609\u20131620. https:\/\/doi.org\/10.1056\/NEJMoa1908655","journal-title":"N Engl J Med"},{"issue":"11","key":"10275_CR23","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS et al (2014) Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"10275_CR24","doi-asserted-by":"publisher","unstructured":"Leizorovicz A, Lechat P, Cucherat M, Bugnard F (2002) Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J 143(2):301\u20137. (In eng). https:\/\/doi.org\/10.1067\/mhj.2002.120768","DOI":"10.1067\/mhj.2002.120768"},{"key":"10275_CR25","doi-asserted-by":"crossref","unstructured":"Investigators CI (1999)\u00a0The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 353(9146):9\u201313. (In eng)","DOI":"10.1016\/S0140-6736(98)11181-9"},{"issue":"15","key":"10275_CR26","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"10275_CR27","doi-asserted-by":"publisher","unstructured":"Majahalme SK, Baruch L, Aknay N et al (2005) Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial). Am J Cardiol 95(4):529\u201332. (In eng).\u00a0https:\/\/doi.org\/10.1016\/j.amjcard.2004.10.026","DOI":"10.1016\/j.amjcard.2004.10.026"},{"issue":"21","key":"10275_CR28","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"10275_CR29","doi-asserted-by":"crossref","unstructured":"Investigators CI (1997)\u00a0Design of the cardiac insufficiency bisoprolol study II (CIBIS II). The CIBIS II Scientific Committee. Fundam Clin Pharmacol 11(2):138\u201342. (In eng)","DOI":"10.1111\/j.1472-8206.1997.tb00181.x"},{"key":"10275_CR30","doi-asserted-by":"publisher","unstructured":"Tsutsui H, Ito H, Kitakaze M et al (2017) Double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of eplerenone in Japanese patients with chronic heart failure (J-EMPHASIS-HF). Circ J 82(1):148\u2013158. (In eng).\u00a0https:\/\/doi.org\/10.1253\/circj.CJ-17-0323","DOI":"10.1253\/circj.CJ-17-0323"},{"key":"10275_CR31","doi-asserted-by":"publisher","unstructured":"Packer M, Fowler MB, Roecker EB et al (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106(17):2194\u20139. (In eng). https:\/\/doi.org\/10.1161\/01.cir.0000035653.72855.bf","DOI":"10.1161\/01.cir.0000035653.72855.bf"},{"issue":"10","key":"10275_CR32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/nejm199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341(10):709\u2013717. https:\/\/doi.org\/10.1056\/nejm199909023411001","journal-title":"N Engl J Med"},{"key":"10275_CR33","doi-asserted-by":"publisher","unstructured":"Consensus Trial Study Group (1987)\u00a0Effects of enalapril on mortality in severe congestive heart failure. New England J Med 316(23):1429\u20131435.\u00a0https:\/\/doi.org\/10.1056\/nejm198706043162301","DOI":"10.1056\/nejm198706043162301"},{"key":"10275_CR34","doi-asserted-by":"publisher","unstructured":"McMurray JJV, Jackson AM, Lam CSP et al (2020) Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation 141(5):338\u2013351. (In eng).\u00a0https:\/\/doi.org\/10.1161\/circulationaha.119.044491","DOI":"10.1161\/circulationaha.119.044491"},{"issue":"16","key":"10275_CR35","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"issue":"1","key":"10275_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2010","unstructured":"Zannad F, McMurray JJV, Krum H et al (2010) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"issue":"14","key":"10275_CR37","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348(14):1309\u20131321. https:\/\/doi.org\/10.1056\/NEJMoa030207","journal-title":"N Engl J Med"},{"key":"10275_CR38","doi-asserted-by":"publisher","unstructured":"Ghali JK, Krause-Steinrauf HJ, Adams KF et al (2003) Gender differences in advanced heart failure: insights from the BEST study. J Am Coll Cardiol 42(12):2128\u201334. (In eng). https:\/\/doi.org\/10.1016\/j.jacc.2003.05.012","DOI":"10.1016\/j.jacc.2003.05.012"},{"issue":"23","key":"10275_CR39","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ et al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359(23):2456\u20132467. https:\/\/doi.org\/10.1056\/NEJMoa0805450","journal-title":"N Engl J Med"},{"key":"10275_CR40","doi-asserted-by":"publisher","unstructured":"Swedberg K, Komajda M, B\u00f6hm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875\u201385. (In eng). https:\/\/doi.org\/10.1016\/s0140-6736(10)61198-1","DOI":"10.1016\/s0140-6736(10)61198-1"},{"key":"10275_CR41","doi-asserted-by":"publisher","unstructured":"Ghali JK, Pi\u00f1a IL, Gottlieb SS, Deedwania PC, Wikstrand JC (2022) Metoprolol CR\/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 105(13):1585\u201391. (In eng).\u00a0https:\/\/doi.org\/10.1161\/01.cir.0000012546.20194.33","DOI":"10.1161\/01.cir.0000012546.20194.33"},{"key":"10275_CR42","doi-asserted-by":"publisher","unstructured":"Young JB, Dunlap ME, Pfeffer MA et al (2004) Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110(17):2618\u201326. (In eng). https:\/\/doi.org\/10.1161\/01.Cir.0000146819.43235.A9","DOI":"10.1161\/01.Cir.0000146819.43235.A9"},{"key":"10275_CR43","doi-asserted-by":"publisher","unstructured":"Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27(19):2338\u201345. (In eng). https:\/\/doi.org\/10.1093\/eurheartj\/ehl250","DOI":"10.1093\/eurheartj\/ehl250"},{"issue":"23","key":"10275_CR44","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345(23):1667\u20131675. https:\/\/doi.org\/10.1056\/NEJMoa010713","journal-title":"N Engl J Med"},{"key":"10275_CR45","doi-asserted-by":"publisher","unstructured":"Lam CS, Carson PE, Anand IS et al (2012) Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circ Heart Fail 5(5):571\u20138. (In eng). https:\/\/doi.org\/10.1161\/circheartfailure.112.970061","DOI":"10.1161\/circheartfailure.112.970061"},{"key":"10275_CR46","doi-asserted-by":"publisher","unstructured":"Merrill M, Sweitzer NK, Lindenfeld J, Kao DP (2019) Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT Trial. JACC Heart Fail 7(3):228\u2013238. (In eng). https:\/\/doi.org\/10.1016\/j.jchf.2019.01.003","DOI":"10.1016\/j.jchf.2019.01.003"},{"issue":"3","key":"10275_CR47","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1161\/01.CIR.103.3.375","volume":"103","author":"T Simon","year":"2001","unstructured":"Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P (2001) Sex differences in the prognosis of congestive heart failure. Circulation 103(3):375\u2013380. https:\/\/doi.org\/10.1161\/01.CIR.103.3.375","journal-title":"Circulation"},{"issue":"2","key":"10275_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2020","unstructured":"Bhatt DL, Szarek M, Steg PG et al (2020) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384(2):117\u2013128. https:\/\/doi.org\/10.1056\/NEJMoa2030183","journal-title":"N Engl J Med"},{"issue":"15","key":"10275_CR49","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383\u20131392. https:\/\/doi.org\/10.1056\/NEJMoa1313731","journal-title":"N Engl J Med"},{"key":"10275_CR50","doi-asserted-by":"publisher","unstructured":"Best Investigators (2001)\u00a0A Trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. New England J Med 344(22):1659\u20131667. https:\/\/doi.org\/10.1056\/nejm200105313442202","DOI":"10.1056\/nejm200105313442202"},{"key":"10275_CR51","doi-asserted-by":"crossref","unstructured":"Danielson C, Lileikyte G, Ouwerkerk W, SP Lam C, Erlinge D, Teng THK (2022) Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta\u2010analysis. ESC Heart Failure","DOI":"10.1002\/ehf2.13974"},{"issue":"2","key":"10275_CR52","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cardfail.2005.09.005","volume":"12","author":"M Galvao","year":"2006","unstructured":"Galvao M, Kalman J, Demarco T et al (2006) Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Cardiac Fail 12(2):100\u2013107. https:\/\/doi.org\/10.1016\/j.cardfail.2005.09.005","journal-title":"J Cardiac Fail"},{"key":"10275_CR53","doi-asserted-by":"crossref","unstructured":"Norberg H (2019) Clinical trial enrolment favours men: fewer women meet eligibility criteria for trials of heart failure medication is discussed by Helena Norberg from Sweden. Oxford University Press","DOI":"10.1093\/eurheartj\/ehz146"},{"issue":"16","key":"10275_CR54","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1093\/eurheartj\/ehi397","volume":"26","author":"N Jochmann","year":"2005","unstructured":"Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V (2005) Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 26(16):1585\u20131595","journal-title":"Eur Heart J"},{"issue":"17","key":"10275_CR55","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1161\/01.CIR.99.17.2334","volume":"99","author":"MC Petrie","year":"1999","unstructured":"Petrie MC, Dawson NF, Murdoch DR, Davie AP, McMurray JJ (1999) Failure of women\u2019s hearts. Circulation 99(17):2334\u20132341","journal-title":"Circulation"},{"issue":"10205","key":"10275_CR56","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/S0140-6736(19)31792-1","volume":"394","author":"BT Santema","year":"2019","unstructured":"Santema BT, Ouwerkerk W, Tromp J et al (2019) Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. The Lancet 394(10205):1254\u20131263","journal-title":"The Lancet"},{"issue":"5","key":"10275_CR57","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0195-668X(02)00823-0","volume":"24","author":"J Cleland","year":"2003","unstructured":"Cleland J, Swedberg K, Follath F et al (2003) The EuroHeart Failure survey programme\u2014a survey on the quality of care among patients with heart failure in Europe: Part 1: patient characteristics and diagnosis. Eur Heart J 24(5):442\u2013463","journal-title":"Eur Heart J"},{"key":"10275_CR58","doi-asserted-by":"publisher","unstructured":"Kuch B, Muscholl M, Luchner A et al (1998) Gender specific differences in left ventricular adaptation to obesity and hypertension. J Hum Hypertens 12(10):685\u201391. (In eng). https:\/\/doi.org\/10.1038\/sj.jhh.1000689","DOI":"10.1038\/sj.jhh.1000689"},{"issue":"47","key":"10275_CR59","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1093\/eurheartj\/ehz835","volume":"40","author":"CSP Lam","year":"2019","unstructured":"Lam CSP, Arnott C, Beale AL et al (2019) Sex differences in heart failure. Eur Heart J 40(47):3859\u20133868c. https:\/\/doi.org\/10.1093\/eurheartj\/ehz835","journal-title":"Eur Heart J"},{"issue":"5","key":"10275_CR60","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1161\/CIRCULATIONAHA.115.015884","volume":"132","author":"AM Shah","year":"2015","unstructured":"Shah AM, Claggett B, Sweitzer NK et al (2015) Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation 132(5):402\u2013414","journal-title":"Circulation"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-022-10275-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-022-10275-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-022-10275-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T20:41:21Z","timestamp":1687552881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-022-10275-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":60,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["10275"],"URL":"https:\/\/doi.org\/10.1007\/s10741-022-10275-1","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"assertion":[{"value":"20 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}